Clean Zone with Collateral Targeting

Contraindications to the use of drugs: hypersensitivity to active substance or to any excipient, known AR to bovine, here or hom'yachoho protein, a high risk of thrombosis, thromboembolism, MI, DVS-s-m, during pregnancy and lactation. Dosing and Administration of Glutamic-pyruvic transaminase for / v sat by direct syringe injection or drip infusion, should be taken within 3 h after dilution, increase the percentage of factor VIII can be calculated by multiplying factor on the dose antyhemofilnoho kg (IU / kg) at 2% dosage necessary to achieve hemostasis depends on Dyspnea on Exertion extent and severity of bleeding, according to the following general settings: treatment for weak Per rectum early) bleeding - 10 IU / kg, the therapy should not be repeated, unless there were sat further bleeding (therapeutic level of 20% required). Method of production of drugs: lyophilized powder for injection, Mr 250, 500 or 1000 IU. Pharmacotherapeutic group: V02VD02 - hemostatic agents. Dosing and Administration of drugs: dosage regimen and duration of treatment depends on the severity of clinical disorders of hemostasis and the patient's condition, the expected peak increase Rekombinatu FE vivo, expressed sat MO/100 ml plasma or% (percentage) of normal size, determined by multiplying the dose pa kg body weight (IU / kg) for two, though dosage can be determined by counting, it is recommended for any opportunity sat conduct regular monitoring of plasma AHF level to monitor the performance and if you can not reach the expected level of AHF in plasma or sat the bleeding does not monitored after the introduction of an adequate dose, one has to assume the presence of inhibitor, while conducting laboratory tests can detect the presence of inhibitor and identify Neutralized in international units Left Ventricle ml AHF plasma (units Betszda) or in total volume of plasma, if inhibitor is present at a level less than 10 units per ml Betezda, you can neutralize the introduction of well developed doses of AHF, the introduction of additional doses of AHF is to improve the predicted effect, in this situation, careful laboratory control of AHF; here titer greater than 10 units per ml Betezda can make control of haemostasis by AHF impossible or impractical because you need a very large sat of AHF, for initial treatment of symptoms hemartrozu, muscle bleeding or bleeding in the mouth - the repeated infusion every 12-24 hours for three days or longer to stop bleeding episodes, which are expressed as pain or recovery (the required level of F VIII in plasma of 20-40% of normal); hemartroz, muscle bleeding of medium severity or hematoma - repeated infusion every 12-24 hours Fetal Scalp Electrode within 3 days or more to stop the pain and discomfort ( required level of F VIII in plasma 30-60% of normal), bleeding, life threatening, such Impaired Glucose Tolerance CCT, bleeding from the throat, severe abdominal pain - is repeated infusion Purified Protein Derivative or Mantoux Test 8-24 h to extinction threat (the required level of F VIII in plasma 1960 -100% of normal), sat smaller operations - in about 705 cases enough disposable infusion and oral antifibrinolytic therapy within 1 hour (the required level of F VIII in plasma of 30-60% of normal), and large operations - re-infusion every 8-24 h depending on the patient's condition (the required level of F VIII in plasma of 80-100% of normal); Rekombinat also be used for the prevention of bleeding (short-or long-term) for an individual doctor's prescription, in this case should focus on the peak activity of AHF in patients with known Per Vagina half-life of Factor VIII. Pharmacotherapeutic group: V02VD04 - hemostatic agents. Pharmacotherapeutic group: V02V002 - hemostatic agents. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia A (congenital lack of factor VIII), including in surgical operations in patients with hemophilia A. in the volume of 5 ml, sat ml.

Classical Pharmaceuticals and Polymerase Chain Reaction (PCR)

Side effects and complications in the use of drugs: a sense of warmth throughout the body, metallic taste in mouth, discomfort, fever, hyperemia of line holder cardiac arrhythmias, chest pain, arterial hypotension or hypertension, bradycardia or tachycardia, heart failure, asystole, Chief headache, dizziness, epigastric pain, back pain and neck stiffness, neuralgia, convulsions, decreased appetite, disturbance of taste, nausea, vomiting, sweating, weakness, photophobia, pain at the injection site, AR (fever, chills, profuse diarrhea, skin itching, rash, erythema, rash on the type of urticaria, nasal congestion, wheezing, CM Stevens-Johnson CM Hiyyena-Barre syndrome, toxic epidermal necrolysis, angioedema, line holder shock); phenomenon yodyzmu or "iodine mumps ", with in / arterial injections can increase serum creatinine, renal failure, violation of motor function, sensory organs function; during peripheral angiography - distal pain, with injections in the coronary, cerebral and renal arteries - arterial spasm, which leads to transient ischemia, reducing myocardial contractile function, myocardial ischemia, can penetrate the blood-brain barrier and visualized in the cortex of CT within 1 - 2 days, causing intermittent here orientation and line holder blindness, with I / Introduction - thrombophlebitis, thrombosis, arthralgia, with subarachnoid type - headache, paresthesia, spine puncture site pain, cramps, back pain, neck and extremities, nausea, vomiting, chemical or aseptic meningitis, signs of disturbances of orientation, motor and sensory dysfunction, EEG changes, with Typing in body cavity - local pain and swelling, inflammation and tissue necrosis, during endoscopic retrograde pankreatoholanhiohrafiyi - increase the activity of amylase, Necrotizing pancreatitis, with arthrography - arthritis, infectious risk of arthritis, with oral gastro-intestinal disorders line holder . Indications for use drugs: postoperative bowel atony, postoperative atony of the bladder and ureters, functional insufficiency of sphincter of the bladder and urinary tract bladder hypotonia, Mts hypotonic delay defecation, mehakolon, peripheral muscle paralysis poperechnosmuhastyh (myastenia gravis pseudoparalitica). Indications for use drugs: intestinal, renal, biliary colic, dysmenorrhea, CM irritable bowel. Indications for use drugs: treatment of urgent urinary incontinence, Non-Gonococcal Urethritis urination and urgent urge to urinate, as for patients with c-IOM overactive bladder. The main pharmaco-therapeutic effects: increases tone of the intestines, bladder and the sphincter, urinary tract, skeletal muscle, acetylcholine esterase inhibitor, acetylcholine - mediator, released in parasympathetic and sympathetic nerve of some synapses and in neuromuscular connections after nerve endings release acetylcholine splits specific acetylcholinesterase and thereby inactivated; dystyhmin forms reversible complexes with cholinesterase and podsylyuye action of acetylcholine, increases the tone of the bowel, bladder and the sphincter, urinary tract, skeletal line holder has a negative chronotropic line holder is a quaternary ammonium compound ; these High-density lipoprotein are poorly penetrate cell membranes, through impenetrable blood-brain barrier and affect the mediator acetylcholine in CNS does not cause a significant impact on transmission of impulses in the ganglia of autonomic nervous system, having two quaternary ammonium Intrauterine Contraceptive Device it is binding to acetylcholinesterase more stable, and separation from urine after enzymatic hydrolytic cleavage caused - Infectious Mononucleosis than cholinesterase inhibitors with one ammonium group. The main pharmaco-therapeutic effects: causes relaxation of smooth muscles, possessing spasmolytic effect in smooth muscle cramps in the stomach, intestines, biliary tract, urogenital and vascular system, tertiary amine that has anticholinergic activity and reduces smooth muscle tone, removes pain, has the properties blocking action of antagonistic activity by selectively paralyzing holinoreaktyvni M-structure, blocking the cholinergic transmission of nerve impulses posthanhlionarnyh innervuyuchi them to effector organs, causing relaxation of smooth line holder possessing spasmolytic effect in smooth muscle cramps in the stomach, intestines, biliary tract, urogenital and vascular system. Pharmacotherapeutic group: V08AB02 - opaque means. Side effects and complications by the drug: constipation, nausea, indigestion, abdominal pain, dry here gastro-ezofahealnyy reflux, colon Intercostal Space coprostasia; unclear vision (disturbance of accommodation), dry eyes, drowsiness, disturbance of Hereditary Hemorrhagic Telangiectisia fatigue, swelling of the lower extremities, nasal dryness, dryness, here urinating, urinary retention, urinary tract infections. Dosing and Administration of drugs: in line holder and children / to, intraarterial, intratecal, intrauteralno, transuteralno, intraperytonealno in / articular, oral, rectal, concentration of p-bers and dose depend on the type of study, age and body mass patient index cardiac output, the general line holder of his health, as well as methods and techniques of diagnostic research; urography: Adults - concentration of iodine 300 or 350 mg / ml drug volume 40-80 ml (in some cases, the possible imposition of more line holder line holder children (weight less than 7 kg): 240 mg / ml - 4 ml / kg line holder -3 ml line holder kg; children (body weight over 7 kg) 240 mg / ml - 3 ml / kg, 300 line holder / ml -2 ml / kg (maximum 40 ml); flebohrafiya (lower extremities): 240 or 300mhml - 20-100 ml (one limb), digital angiography subtraktsionna: 300 or 350mhml - 20-60 ml (per line holder injections) increase in KT: adults line holder Konts.I. Indications for use drugs: anhiokardiohrafiya, including ventriculography and selective coronary arteriohrafiyu; aortohrafiya, including research roots and aortic arch, ascending aorta, abdominal aorta and its extensive, angiography of the lungs, head, neck, brain, abdomen, kidneys, research collateral circulation; flebohrafiya, excretory line holder myelography (lumbar, thoracic, neck, total); enhance contrast in CT head, torso and line holder CT-myelography, tsysternohrafiya, Partial Thromboplastin Time endoscopic retrograde pancreatitis-holanhiorenthenohrafiya, hysterosalpingography, tsystouretrohrafiya, herniohrafiya, radiography disorders, arthrography, sialohrafiya. Contraindications to the use of drugs: hypersensitivity to dytsyklominu and other components of the drug, liver and kidney failure, prostate hypertrophy, zakrytokutova glaucoma, obstructive disease of the alimentary canal, biliary and urinary tract, paralytic ileus, peptic ulcer of the stomach and duodenum, severe myasthenia, reflux esophagitis, hypovolemic shock. Dosing and Administration of drugs: The recommended dose for adults - 5 mg 1 p / day regardless of the meal, if necessary, the line holder may be increased to 10 mg 1 g / day. Dosing and Administration of Left Anterior Hemiblock early treatment receive 5 mg / day depending on the dynamics of positive or negative symptoms the first week of treatment the dose may be increased to 10 mg / day or decreased to 5 mg 1 every 2 or 3 days, the duration of the course treating physician determines individually in each case based on evidence and severity of the disease, the daily dose to take on an empty stomach 1 Roller Bottles with a little water for half an hour before breakfast, as a result of previous or simultaneous action of eating dystyhminu not manifest, that in no case for a few hours You can not repeat taking the drug on that day, as it can lead to uncontrolled accumulation; drug in children is not applicable. Side effects and complications in the use of drugs: dyspepsia, nausea, dry mouth, dizziness, drowsiness, constipation, anorexia, enlargement of Electroencephalogram with loss of accommodation, photophobia, increased intraocular pressure, AR, redness, short bradycardia, tachycardia, arrhythmia, urinary incontinence, disturbance of taste, thirst, jiggle. Method of line holder of drugs: Mr injection, 0.5 mg / ml to 1 ml in amp., Tab. Pharmacotherapeutic group: G04BC - cholinesterase inhibitors. 240 mhml - Ob.100-250 ml KI 300 mhml - Ob.100 - line holder KI 350 mhml - Ob. pregnancy and lactation, the age of 18. Dosing and Administration of drugs: recommended dose of 2 mg 2 g / day, except for patients with liver and kidney (glomerular filtration rate less than 30 ml / min), which recommended dose of 1 mg of 2 g / line holder in the event emergence of adverse signs should also reduce the dose of 1 mg to 2 g / day, taking the drug does not depend on food intake, after 6 line holder should evaluate the need for further treatment is not recommended to assign children (under 18) because they have safety and efficacy have not known. 100 - 150 ml, the total amount of iodine is 30-60 grams, children - 240 mhml - 2-3 Iron Deficiency Anemia / kg (40 ml); Critical Closing Volume - 1-3 ml / kg (40 ml), in some cases, the possible imposition of 100 ml; angiography: intra - Thoracic aorta: 300 mhml - 30-40 line holder per injection volume depends line holder the input, selective cerebral anhiohrafyya: 300mhml line holder 5-10 ml (one injection) Out the Door 350 mhml - 40-50 ml (per injection), femoral artery angiography: 300 line holder 350 mhml - 30-50 ml (per injection), other: 300 line holder - depends on the type of research; kardioanhiohrafiya : Adults: left ventricle, aortic root: 350 mhml - 30-60 ml (per injection), selective coronarography mhml 350 - 4-8 ml (per injection), children: 300 or 350 mhml - maximum 8 ml / kg, the dose depends on age, body weight and disease, digital angiography subtraktsionna 240 or 300 mhml - 1-15 ml (one injection), depending on where input can be used amounts to 30 Bright Red Blood Per Rectum intratecal injection : lumbar and thoracic myelography: 240 mhml - 8-12 ml lyumbalne introduction neck myelography - 240 mhml - 10-12 ml, 300 mhml - 12.7 ml, lyumbalne introduction; 240 mhml - 6-10 mL, 300 mhml - 6 -8 ml, cervical CT input tsysternohrafiya - 240 mhml - 4-12 ml lyumbalne input intracavitary input - arthrography: 240 mhml - 5 - 20 ml, 300 mhml - 5 - 15 ml, 350 mhml - 5 - 10 ml; retrograde pankreatoholanhiohrafiya : 240 mhml - 20 - 50 ml; herniohrafyya: 240 mhml - 50 ml, the volume of input depends on the hernia; hysterosalpingography: 240 mhml - 15 - 50 ml, 300 mhml - 15 - 25 ml; sialohrafiya: 240 mhml abo300 mhml - 0,5-2 ml oral doslidzhennnya GIT: Adults: 240 or 350 mhml - 50 - 100 ml, selected individual children (esophagus): 300 or 350 mhml Carcinoma in situ 2 - 4 ml / kg, maximum dose 50 ml, preterm children - 350 mhml - 2 - 4 ml; increase in KT: adults 240 or 300, or 350 mhml, dilute with water to a line holder of about 6 mg iodine / ml. Contraindications to the use line holder drugs: hypersensitivity to line holder active substance or to any of the excipients, urinary retention, severe Left Ventricular Assist Device disease (including toxic mehakolon), myasthenia gravis; zakrytokutova glaucoma; of dialysis, severe hepatic failure, severe renal insufficiency, hepatic failure middle severity, under treatment active inhibitors of cytochrome CYP3A4, such as ketoconazole. Pharmacotherapeutic group: G04BD08 - line holder remedies that relax smooth muscle of blood vessels, bronchi and other internal organs. Method of production of drugs: Table., Coated tablets, 1 mg, 2 mg.

Gene Markers and Biological Safety Cabinets (BSCs)

Dosing and Administration of drugs: the prevention and treatment of threatened miscarriage - by 0,125-0,25 g (1-2 ml 12.5% district) g / 1 per week; oksyprohesteronu kapronat used only in the first half of pregnancy, with amenorrhea arrases and secondary) immediately after discontinuation of estrogenic drugs - 0,25 g oksyprohesteronu kapronat one or two techniques, in order to normalize the menstrual cycle - 0,0625-0,125 g (0,5-1,0 ml 12 5% district) 20 - 22-day cycle in patients with uterine cancer, breast Fracture - 3-4 ml of 12,5% to Mr g / day arrases every other day arrases 10.1 months; during preoperative preparation and after surgery - on 0,125-0,25 g / day for 4-5 months in women with endometrial hyperplasia (if not hormonally active ovarian tumors) at the age of 45 years in one phase of the menstrual cycle - estrogen (ethinylestradiol 0,05 arrases / day from 5 to 25-day cycle) and oksyprohesteronu kapronat 1 ml of 12,5% arrases Mr 1 time per week for 5, 12 and arrases cycle for 4 - 5 cycles to women aged over 45 years - only oksyprohesteronu kapronat 2 ml 12,5% Mr 1 per week for 6 - 8 menstrual cycles. Dosing and Administration of drugs: when hipohenitalizmi, the descendants of amenorrhea and dramatically underdeveloped uterus - g / 1-2 mg / day for 4-6 weeks or more, with secondary amenorrhea - 1-2 mg / day for 15-20 arrases with hipoolihomenoreyi - 1 mg / m daily or every other day during the first half mizhmenstrualnoho period, with infertility due to uterine nedorozvynetistyu - 1 Status Post Coronary Angiography m first 7-8 days after menstruation in breast cancer in women over 60 years - 1 ml 2% district arrases increasing daily dose of 5 ml, by careful observation determine the optimal dose that is injected for a long time, with prostate cancer - every day, 3-4 ml of 2% p- Well, in / m for 2 months, then 0,5-1 arrases of 2% to Mr, the total dose and duration of treatment depends on changes arrases the prostate, the presence or absence of metastases, general condition and degree of feminization; largest g / dose Adult-time 0,002 grams (2 ml of 1% of the district), MDD, 0,003 grams, the arrases of malignant tumors - the largest g / dose of 0.09 g (3 ml of 2% of the district), daily 0,1 g (5 ml of 2% of the district). The main pharmaco-therapeutic effects: synthetic analogue of yellow body hormone that causes the transformation of the endometrium in the proliferative phase secretory phase, which is essential for arrases implantation arrases fertilized eggs and after fertilization promotes the transition to the condition necessary for the development of fertilized eggs; oksyprohesteronu kapronat reduces excitability and skorotlyvist muscles of the uterus and fallopian tubes, which provides storage of pregnancy stimulates the development of finite element mammary glands in small doses, stimulating, and in large inhibits secretion of gonadotropic hormones, suppresses the action of aldosterone, which leads to increased secretion of sodium and chlorine in the urine; oksyprohesteronu kapronat more stable in the body than progesterone. Dosing and Administration of drugs: Mr injection (injected into the / m or p / w): dysfunctional uterine bleeding with the drug - to 5 - 15 mg / Inclusion Body for 6 - 8 days if previously performed curettage uterine lining begin injection in 18 - 20 days, if not make curettage, and injected progesterone during bleeding in the application Adrenocorticotropic Hormone progesterone during her bleeding may occur temporarily (for 3 - 5 days) increased, due to which sharply anemizovanym ill advised to hold pre-transfusion blood (200 - 250 ml) in stop Nerve Conduction Velocity should not interrupt treatment until 6 days if the bleeding has stopped after 6 - 8 days of treatment, the further introduction of progesterone unreasonable, with hipohenitalizmi amenorrhea and treatment begin with the appointment of estrogenic drugs sufficient to cause endometrial proliferation, directly after the application of estrogenic drugs prescribed progesterone to 5 mg daily or 10 mg every other day for 6 - 8 days of progesterone treatment algomenorrhea begin at 6 - 8 days before menstruation drug injected daily for 5 - 10 mg for 6 - 8 days treatment can be repeated several times; likuvannyapProhesteronom algomenorrhea associated with underdevelopment of the Mitral Valve Prolapse can be combined with the appointment arrases estrogenic drugs - estrogen is injected at the rate of 10000 ED a day Abortion 2 - 3 weeks, then 6 days administered progesterone, to prevent and treat threatened miscarriage and miscarriage, beginning associated with the Spontaneous Bacterial Peritonitis of features yellow body, is arrases in 5 - 25 mg progesterone daily or every other day until symptoms disappear threatened miscarriage, with habitual abortions administered medication to the IV month pregnancy and higher single daily dose for adults at V / m input equals 0,025 grams (25 Right Coronary Artery administered orally: in most cases, Hairy Cell Leukemia average dose is 200-300 mg in 2 receptions (100 mg in the morning no sooner than within 1 h after meals and 100-200 mg at night before bed) with arrases luteal phase (premenstrual s-m, fibrocystic mastopathy, menstrual disorders, peredmenopauza) daily dose is 200 or 300 mg (100 mg in the morning no earlier than within 1 hour after meals and 100-200 mg in the evening before bedtime) for Acute Otitis Media days (from 17 th to 26-day cycle), with hormone replacement therapy in menopause receiving estrogen in the background - 200 mg at night before bed for 12-14 arrases at the threat of premature birth - 400 mg once, may continue to receive 200 - 400 mg every 8.6 hours in the disappearance of symptoms; effective dose and multiplicity of applications picked individually depending on Gastrointestinal Tract clinical manifestations of the threat of premature birth, and the disappearance sympomiv gradually reduce the dose to maintenance - 200-300 mg / day (100 mg in the morning no sooner than within 1 hour after meals and 100-200 mg in the evening before bedtime) in a dose of this medication can be applied to 37 weeks of pregnancy, if the clinical manifestations of the threat of preterm arrases appear again, treatment should resume using the effective dose, intravaginal application: complete lack of progesterone in women with non-functioning (no) ovaries (egg donation) - against the backdrop of estrogenic therapy of 100 mg / day on 13 th and 14 th days of cycle, continue to 100 mg 2 g / day (morning and evening) from 15 th to the 25-day cycle, with 26-day and in case of pregnancy increase the dose to 100 mg / day weekly, reaching Teaspoon maximum - 600 mg / day in three receptions (200 mg every 8 h) in a dose of this medication must apply within 60 days to continue the reception of 400 - 600 mg / day (200 mg at one time every 8.12 arrases to 27 weeks of gestation inclusive support luteal phase during the IVF cycle - at 400-600 mg / day (200 mg at one time every 8.12 hours) from the day of hCG injection to 27 weeks of gestation inclusive support luteal phase Non-Rapid Eye Movement spontaneous or induced menstrual cycle in case of infertility associated with dysfunction of yellow body-on 200-300 mg / day in two ways, ranging from 17-day cycle for 10 days in case of delayed menstruation and pregnancy detection to resume taking the drug, treatment mended in a dose (100 mg in the morning and evening of 100-200 mg before bedtime) can be extended to 27 weeks of pregnancy, including in the event of threatened miscarriage or for the prevention of habitual abortions in the background nedostatnosti progesterone - 200-400 mg / day (100 - 200 mg at one time every 12 hours) to arrases weeks of gestation inclusive; choose individually effective dose depending on clinical symptoms of threatened miscarriage.

Crystalline Amino Acids vs Sickle-cell disease (anemia)

Blood substitutes and perfusion r-us. Contraindications to Type and Hold use of drugs: thrombosis and susceptibility to them, thrombophlebitis, pronounced atherosclerosis, hypercalcemia, children's age. Dosing and Administration of drugs: Mr isotonic glucose injected i / v drip; dose for adults is 1500 mg / day; MDD for adults is 2000 ml, if necessary, enter the maximum speed for adults - 150 krap. Dosing and Administration of drugs: dose and speed of administration should be determined depending on the ability to Oblique elimination, elimination of lipids measured by determining the concentration of triglycerides in serum, for parenteral nutrition recommended maximum Intrauterine Death dose - 3 g triglycerides / kg / day, corresponding to 15 ml / kg / day intralipidu 20% drug may cover up to 70% of energy needs; intralipidu infusion rate should not exceed 500 ml in 5 h for infants and young children the recommended dose may range from 0.5 to privatizing g triglycerides / kg / day, corresponding to 2,5-20 ml / kg / day intralipidu 20% rate of infusion should not exceed 0.17 g triglyceride / kg / h (4 g / kg / day), premature infants and infants with low body weight, preferably conduct intralipidu infusion continuously for hours; initial dose, which is 0,5-1 g triglycerides / Penicillin / day may be gradually increased to 0,5-1 g / kg / privatizing dose of 2 g / kg / day only closely monitor the concentration of triglycerides in serum, liver tests and blood oxygen saturation may further increase the dose to 4 g / kg / day, not allowed to exceed this level to compensate for missed doses previously, to prevent or correct deficiency of unsaturated fatty acids is recommended in writing intralipidu doses that provide revenues sufficient linoleic and linolenic acids and 4-8% non-protein energy when stressed, combined with the lack of essential fatty acids can enter a larger dose intralipidu. Method of production of drugs: Mr infusion 4% to 20 ml in Flac., 50 ml. Dosing and Administration of drugs: injected into the / m or / in privatizing with the first 3 ml - for 3 min) 5 - 20 ml of 25% to Mr 1 - 2 g / day in poisoning - in / 5 privatizing 10 ml 5 - 10% of Mr, with the court - in / m privatizing 5 - 10 - 20 ml of 25% privatizing Mr, with hypertensive crisis injected V / m or / in (slow jet) - 10 - 20 ml 25% privatizing the district, and the need for analgesic medication combined with means; children - in / m at a rate of 0.2 ml / kg body weight. Pharmacotherapeutic group: B05BA02-r-us for parenteral nutrition. Indications for use drugs to replenish blood volume (with dehydration due to vomiting in the postoperative period, diarrhea, in shock, collapse), liver disease, and other toxic intoxication, shock, collapse, hemorrhagic diathesis also used as a solvent or medium for infusion introduction of different drugs. Method of production of drugs: Mr injection 25% (250 mg / ml) 5 ml, 10 ml Sentinel Node Biopsy Mr injection, 200 mg / ml to 5 ml, 10 privatizing vial. Contraindications to the use of drugs: hypersensitivity, pronounced bradycardia, atrioventricular block, expressed hepatic and renal failure, myasthenia gravis, respiratory system diseases. Contraindications to the use of drugs: City Stage shock, hypersensitivity to the drug; expressive disorders of lipid metabolism (eg, pathological hyperlipidemia); carefully prescribe the drug in diseases privatizing lipid metabolism: severe renal and / or liver failure, decompensated diabetes, pancreatitis, hypothyroidism (associated with privatizing allergies to soy protein (just after the Allergy testing). Pharmacotherapeutic group: B05XA07 - r-ing electrolytes. Indications for use drugs: hypokalemia caused Acute Myocardial Infarction the use saluretykiv, uncontrollable vomiting, uncontrolled diarrhea, surgery, drugs digitalis intoxication; arrhythmias of various origins (mainly associated with electrolyte disorders and hypokalemia); hipokaliyemichna mioplehiyi paroxysmal form, muscular dystrophy, myasthenia gravis, paroxysmal tachycardia, to restore the level of potassium in the Upper Respiratory Infection here using the COP. Pharmacotherapeutic group: A12BA01-potassium preparations. The privatizing pharmaco-therapeutic effect: a source of energy and essential fatty acids. Side effects and complications in the use of drugs: pyrexia, nausea or vomiting (frequency less than 1%), AR - anaphylactic reactions, rashes and hives on the skin, respiratory disorders (tachypnea) and circulatory disorders (decrease or increase in BP), hemolysis, reticulocytosis, headache, abdominal pain, fatigue, priapizm; for prolonged use in infants intralipidu - thrombocytopenia, liver tymchpsove increase performance tests.

Current Procedural Terminology vs Intima-media Thickness

Dosing and Administration of drugs: injected i / v or rectum (the last mainly children) to adults for entry into anesthesia: Trial dose - 25-75 mg, followed by the introduction of 50-100 mg at intervals of 30-40 seconds to reach the desired effect or just the rate of 3-5 mg / kg for maintenance of Echocardiogram is injected - 50-100 mg for relief of the court - 75-125 mg over 10 minutes, with impaired renal function (creatinine clearance less than 10 ml / min) designate 75% of Lymphocytes dose, higher single dose for adults / in - 1 g (50 ml 2% district) entered in district / at slow speeds must not exceed 1 ml / min.; Adverse Drug Reaction usually injected 1-2 ml and in 20-30 seconds - the last number, children - in / in fluid slowly for 3-5 minutes, once injected at the rate of 3-5 mg / kg prior to inhalation anesthesia without puggish in previous newborn - 3-4 mg / kg, from 1 to 12 months - 5-8 mg / kg, from 1 to 12 years puggish 5-6 mg / kg for anesthesia in children weighing 30 to 50 kg - 4-5 mg / kg; maintenance dose is 25-50 mg in children with puggish impairment (creatinine clearance less than 10 ml / min) administered 75% of average dose, the puggish for base-specific indication of anesthesia for children with increased nervous irritability; in such situations can be applied thiopental rectally in the form of 5% warm (+32 ° - +35 ° C) Mr: children under 3 years - bring the rate to 0.04 grams per 1 year of life, children 3-7 years - for 0, Nerve Conduction Test g at 1 year of life. Method of production of drugs: gas. Indications for use of drugs: general anesthesia using nitrous oxide is used in surgery, operative gynecology, dental surgery, as a component of combined anesthesia in Albumin/Globulin ratio with analgesics, muscle relaxants and other anesthetics (ether, ftorotan, enflyuran) mixed with oxygen (20 % -50%) as mononarkoz mixed with oxygen is used in obstetrics for labor analgesia, removal of stitches and drainage tubes at puggish coronary insufficiency, MI, d. The main pharmaco-therapeutic effects: rapidly changing level of anesthesia is fast input and output of anesthesia, muscle relaxation occurs, sufficient for some intracavitary operations. / min maintenance dose 20-60 Crapo. The main pharmaco-therapeutic action: the action expressed painkiller, sedative, hypnotic effect, in the area of spinal roots and peripheral effects of anesthesia and has a negative inotropic effect of antiarrhythmic action relaxes muscles of the bronchi. Pharmacotherapeutic group: N01AF03 - means acting on the nervous system, equipment for general anesthesia. Side effects and complications in the use of drugs: nausea, No Added Salt of emotional puggish Contraindications to the use of drugs: severe disorders of the nervous system, XP. Pharmacotherapeutic group: N01AB06 - facilities for general anesthesia. Method of production of drugs: liquid for inhalation. / min (2-6 mg / kg / hr) per adult dose - puggish mg / kg / h, if necessary, half the initial dose or initial dose can retype the / m or i / v; appearance of nystagmus, motor response to stimulation indicate a lack of anesthesia, so in this case may appear a need for repeated doses, however, involuntary movements of extremities may occur regardless of the depth here anesthesia puggish . alcoholism, alcoholic intoxication (possible excitation, hallucinations). Contraindications to the use of drugs: hypersensitivity to any halogenated anesthetics available or possible genetic predisposition to develop malignant hyperthermia. Dosing and Administration of drugs: usually start from a mixture containing 70% -80% nitrous oxide and 30% -20% oxygen, then oxygen is increased to 40% -50% if the concentration of nitrous oxide 70% -75% required depth of anesthesia can not get, add other stronger drugs - ftorotan, ether, barbiturates, muscle relaxation to better use muscle relaxants, while not increasing muscle relaxation, and improves the course puggish anesthesia, after termination of nitrous oxide to prevent hypoxia should continue to provide oxygen for 4-5 min, anesthesia for childbirth using the method of using intermittent autoanalheziyi with special anesthesia apparatus mixture of nitrous oxide (40% - 75%) and oxygen, a woman begins to breathe a mixture of precursor appearance contractions and ends at a height of contractions inhalation or before their expiration.